NCT02287818View on ClinicalTrials.gov

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 27, 2016

Study Completion Date

October 27, 2016

Conditions
Gout
Interventions
DRUG

Placebo

Placebo twice daily from Day 1 to Week 12

DRUG

AC-201

AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12

DRUG

Febuxostat

Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL

Trial Locations (1)

112

Taipei Veteran General Hospital (TVGH), Taipei

All Listed Sponsors
lead

TWi Biotechnology, Inc.

INDUSTRY

NCT02287818 - A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout | Biotech Hunter | Biotech Hunter